EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL

Author(s):
Mease, P.J.; Hall, S.; FitzGerald, O.; Heijde, D. van der; Merola, J.F.; Avila-Zapata, F.; Cieslak, D.; Graham, D.; Wang, C.; Menon, S.; Hendrikx, T.; Kanik, K.S.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-06-30
Language
English
Is part of
Annals of the Rheumatic Diseases (2017), Vol. 76, p. 141-142
hdl
1887/116171
doi
10.1136/annrheumdis-2017-eular.1416